Oncocliffe offers high quality, accurate and reliable testing of Liquid biopsies
Oncocliffe Liquid Biopsy protocols target the cfDNA in blood which can be easily drawn from patients with minimal invasiveness (Liquid Biopsy) and can be used for diagnosis, prognosis, recurrence-risk prediction, or can be biopted at regular intervals to dynamically monitor disease progression, drug response and to customize cancer care. cfDNA assays also prove useful in detecting resistance mutations to tyrosine kinase inhibitors. Oncocliffe offers high quality, accurate and reliable testing of Liquid biopsies for identification of most common genetic alterations.
The Oncocliffe Pan Cancer cell-free assay is multibiomarker next-generation sequencing (NGS) assay that enable reliable detection of somatic mutations in plasma, for genes relevant to solid tumors.
Genes Covered
| Genes | CNV | Fusions | Extra | |||
|---|---|---|---|---|---|---|
| AKT1 | CTNNB1 | GNAQ | NTRK1 | CCND1 | ALK | Met Exon 14 skipping |
| ALK | DDR2 | GNAS | NTRK3 | CCND2 | BRAF | |
| APC | EGFR | HRAS | PDGFRA | CCND3 | ERG | |
| AR | ERBB2 | IDH1 | PIK3CA | CDK4 | ETV1 | |
| ARAF | ERBB3 | IDH2 | PTEN | CDK6 | FGFR1 | |
| BRAF | ERG | KIT | RAF1 | EGFR | FGFR2 | |
| CCND1 | ESR1 | KRAS | RET | ERBB2 | FGFR3 | |
| CCND2 | ETV1 | MAP2K1 | ROS1 | FGFR1 | MET | |
| CCND3 | FBXW7 | MAP2K2 | SF3B1 | FGFR2 | NTRK1 | |
| CDK4 | FGFR1 | MET | SMAD4 | FGFR3 | NTRK3 | |
| CDK6 | FGFR2 | MTOR | SMO | MET | RET | |
| CHEK2 | FGFR3 | MYC | TP53 | MYC | ROS1 | |
| FLT3 | FGFR4 | NRAS | GNA11 | |||
Genes Covered : ALK, BRAF, EGFR, ERBB2, KRAS, MAP2K1, MET, NRAS, PIK3CA, RET, ROS1 and TP53 (169 Hot spots and 49 Fusions of ALK, RET, ROS1 and CNV of MET).
Genes Covered : AKT1, CCND1, EGFR, ERBB2, ERBB3, ESR1, FBXW7, FGFR1, KRAS, PIK3CA, SF3B1 and TP53 (152 Hot spot mutations and CNVs of CCND1, ERBB2, FGFR1).
Genes Covered : AKT1, APC, BRAF, CTNNB1, EGFR, ERBB2, FBXW7, GNAS, KRAS, MAP2K1, NRAS, PIK3CA, SMAD4 and TP53 (236 Hotspots)
10 ml whole blood in Streck Tube
4-8℃
3-4 weeks
| Test Code | Description | Methodology | TAT | Sample Details | Transportation | |
|---|---|---|---|---|---|---|
| RCL508 | Oncocliffe Liquid biopsy Pan cancer cell free assay- 52 genes (12 CNV genes, 96 fusions from 12 genes, MET exon 14 skipping) | NGS | 30 Days | Whole Blood in Streck (BCT -Cell free DNA)Tube | 9-10 ml Whole Blood in BCT tube | |
| RCL509 | Oncocliffe Liquid Biopsy- Lung cf Total Nucleic acid assay (11 Gens, 169 Hot spots and 49 Fusions of ALK, RET, ROS1 and CNV of MET) | NGS | 30 Days | Whole Blood in Streck (BCT -Cell free DNA)Tube | 9-10 ml Whole Blood in BCT tube | |
| RCL510 | Oncocliffe Liquid Biopsy - Breast cfDNA assay (10 Genes, 152 Hot spot mutations and CNVs of CCND1, ERBB2, FGFR1 ) | NGS | 30 Days | Whole Blood in Streck (BCT -Cell free DNA)Tube | 9-10 ml Whole Blood in BCT tube | |
| RCL511 | Oncocliffe Liquid Biopsy- Colon cfDNA assay (14 genes, 236 Hot spots) | NGS | 30 Days | Whole Blood in Streck (BCT -Cell free DNA)Tube | 9-10 ml Whole Blood in BCT tube | |
| RCL512 | Oncocliffe Liquid Biopsy- Hot Spot Mutations Panel (SNP only) 50 Genes | NGS | 30 Days | Whole Blood in Streck (BCT -Cell free DNA)Tube | 9-10 ml Whole Blood in BCT tube |